Overcoming resistance in Her2-positive metastatic breast cancer

被引：0
|
作者：
Oksuzoglu, Omur Berna [1 ,2 ]
机构：
[1] Erzincan Univ, Fac Med, Dept Internal Med, Med Oncol, Erzincan, Turkey
[2] A Yurtaslan Ankara Oncol Traning & Res Hosp, Dept Med Oncol, Ankara, Turkey
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-22
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey, Naomi
    Sandoval, Ana
    Mahtani, Reshma
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1120 - 1137
  • [32] NEW DRUG APPROVED FOR HER2-POSITIVE METASTATIC BREAST CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (04) : 23 - 23
  • [33] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [34] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [35] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [36] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Naomi Dempsey
    Ana Sandoval
    Reshma Mahtani
    Current Treatment Options in Oncology, 2023, 24 (9) : 1120 - 1137
  • [37] ASCO 2018: highlights in HER2-positive metastatic breast cancer
    Bartsch R.
    Bergen E.
    memo - Magazine of European Medical Oncology, 2018, 11 (4) : 280 - 283
  • [38] ASCO 2019: highlights in HER2-positive metastatic breast cancer
    Rupert Bartsch
    Elisabeth Bergen
    memo - Magazine of European Medical Oncology, 2019, 12 : 308 - 311
  • [39] Current and Future Management of HER2-Positive Metastatic Breast Cancer
    Martinez-Saez, Olga
    Prat, Aleix
    JCO ONCOLOGY PRACTICE, 2021, 17 (10) : 594 - +
  • [40] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
12345